Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - March 2012 (Related Reports)

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - March 2012


March 27, 2012
68 Pages - SKU: GBDT3824130
License type:
Online Download      US $1,000.00
Global Site License      US $3,000.00
Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023
4/7/2014 | published by: Kalorama Information
Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 Kalorama Information's Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical  |  read more...
$3,995.00
Retail Clinics Market Overview and 2014 Survey Results
3/11/2014 | published by: Kalorama Information
Retail Clinics Market Overview and 2014 Survey Results Retail clinics are medical settings located in a retail store. They are not free standing and do not offer all medical  |  read more...
$750.00
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014
4/15/2014 | published by: GlobalData
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014 provides data on the  |  read more...
$2,500.00
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Global Clinical Trials Review, H1, 2014
4/15/2014 | published by: GlobalData
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Global Clinical Trials Review, H1, 2014 provides data on the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) clinical  |  read more...
$2,500.00
Recurrent Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2014
4/15/2014 | published by: GlobalData
Recurrent Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Recurrent Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2014 provides data on the Recurrent Glioblastoma Multiforme (GBM) clinical trial scenario. This  |  read more...
$2,500.00
Psoriasis Market Info™- Customized Report
4/4/2014 | published by: Drug Market Info
 |  read more...
$13,250.00
Sri Lanka Pharmaceuticals and Healthcare Report Q2 2014
4/16/2014 | published by: Business Monitor International
Sri Lanka Pharmaceuticals and Healthcare Report Q2 2014 BMI View: A better-than-expected outlook for Sri Lanka's economy has led us to upwardly revise ourpharmaceutical and healthcare forecasts. The government has introduced price controls on wholesale andretail  |  read more...
$1,295.00
Venezuela Pharmaceuticals and Healthcare Report Q2 2014
4/16/2014 | published by: Business Monitor International
Venezuela Pharmaceuticals and Healthcare Report Q2 2014 BMI View: Foreign currency controls and drug price cuts will continue to affect pharmaceutical companies'profitability, with the currency devaluation and high inflation exacerbating the situation. A closerelationship and effective  |  read more...
$1,295.00
Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014
4/15/2014 | published by: GlobalData
Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014 provides data on the Recurrent Malignant Glioma clinical trial scenario. This report provides elemental  |  read more...
$2,500.00
Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014
4/15/2014 | published by: GlobalData
Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014 provides data on the Metastatic Ovarian Cancer clinical trial scenario. This report provides elemental  |  read more...
$2,500.00